The results challenged the use of combined oral anticoagulant and antiplatelet therapy in patients with atrial fibrillation, especially those without an indication for antiplatelet therapy.
The University of Nottingham’s Division of Primary Care investigated the risks and benefits of the three most common types of direct anti-coagulants (DOACs), apixaban, dabigatran and rivaroxaban, compared with the current main treatment warfarin for patie